Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information untess it contains a valid CMB control number.

Supplitute for form 1449A/PTO

Sheet

DEC 2 3

THADE

FORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/678,371

Filing Date October 3, 2003

First Named Inventor Benjamin V. Treadwell

Group Art Unit

Examiner Name

(use as many sheets as necessary)
eet 1 of 3

Attorney Docket Number 030229

	U.S. PATENT DOCUMENTS						
Exeminer tritials *	Cite No.1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pagea, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
2	-	US- 3,031,376	4/24/1962	Levin et al.			
7,		US- 3,863,633	2/4/1975	Ryde et al.			
		US- 4,623,667	11/18/1988	Gans et al.			
		US- 4,670,471	6/2/1987	Clark			
	1	US-4,874,794	10/17/1989	Katz			
	i -	US- 5,071,879	12/10/1991	Katz			
		US- 5,135,958	8/4/1992	Borg et al.			
		US-5,186,219	11/24/1992	Katz			
		US- 5,194,451	3/16/1993	Katz			
		US- 5,534,554	7/9/1998	Katz et al.			
		US- 5,683,158	9/2/1997	Granja et al.			
		US- 5,843,919	12/1/1998	Burger			
		US- 5,856,318	1/5/1999	Granja et al.			
		US- 5,952,393	9/14/1999	Sorkin, Jr.			
		US- 6,121,319	9/19/2000	Somers			
		US- 6,136,795	10/24/2000	Florio			
		US- 6,197,832	3/6/2001	Sorkin, Jr.			
		US- 8,225,354	5/1/2001	Perez			
	i i	US- 6,245,811	6/12/2001	Horrobin et al.			
17		US- 2001/0006656A1	7/5/2001	Harlan et al.			
─ V		US- 6,303,139	10/16/2001	Passi et al.			
-,/	1	US- 2001/0034338A1	10/25/2001	Sorkin, Jr.			

		FOREIGN PA	HENI DOCU	MENIS		
		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	İ
Examiner Initials*	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ^d

Examiner Signature	~	Date Considered	3/11/09	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).
 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).
 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.
 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

UP TOTAL TOTAL 1449APTO

STORMATION DISCLOSURE

STATEMENT BY APPLICANT

Complet if Known

Application Number 10/678,371

Filing Date October 3, 2003

First Named Inventor Benjamin V. Treadwell

Group Art Unit

Examiner Name

(use as many sheets as necessary)

Sheet 2 of 3 Attorney Docket Number 030229

			U.S. PATENT	Name of Patentee or Applicant of	
Examiner Initials *	Cite No.	Cite No.1 Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Relev Passages or Relevant Figures Appear
3/		US- 2001/0034384A1	10/25/2001	Gasper et al.	
7.		US- 6,313,179	11/6/2001	Pope et al.	
		US- 6,355,274	3/12/2002	Dartey et al.	
		US- 2002/0077381A1	6/20/2002	Peet et al.	
		US- 2002/0077317A1	6/20/2002	Das	
		US- 2002/0099099A1	7/25/2002	Gamble et al.	
		US- 6,438,431	8/20/2002	. Hoffpauer et al.	
		US- 2002/0132035A1	9/19/2002	Tamarkin et al.	
- I		US- 2002/0156122A1	10/24/2002	Mach	
_		US- 2002/0159973A1	10/31/2002	Mach	
		US- 2002/0159974A1	10/31/2002	Mach	
	$\overline{}$	US- 2002/0161026A1	10/31/2002	Paraikar	
		US- 6,525,083	2/25/2003	Acton, III et al.	
		US- 2003/0054978A1	3/20/2003	Babish	
		US- 6,537,980	3/25/2003	Hansen	
		US- 2003/0060488A1	3/27/2003	Sugiyama et al.	
		US- 2003/0060500A1	3/27/2003	Mach	
		US- 2003/0080501A1	3/27/2003	Mach	
		US- 2003/0080502A1	3/27/2003	Mach	
	Î	US- 2003/0065019A1	4/3/2003	Mach	
	T	US- 6,548,715	4/15/2003	Bouillon et al.	
		US- 6,559,174	5/8/2003	Lin et al.	
		US- 2003/0096876A1	5/22/2003	Gamble et al.	
1,	1	US- 6,569,481	5/27/2003	Tillyer et al.	
1/		US- 6,573,255	6/3/2003	. Bretting	
~ /	7	US- 6,613,920	9/2/2003	Steinmeyer et al.	

	FOREIGN PATENT DOCUMENTS							
	011-	Foreign Patent Document	D. A. Carriera	Name of Patentee or	Pages, Columns, Lines, Where Relevant			
Examiner Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T°		

Examiner Signature	Date Considered	3/16/09

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional) . ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet-

Complete if Known				
Application Number	10/678,371			
Filing Date	October 3, 2003	_		
First Named Inventor	Benjamin V. Treadwell			
Group Art Unit				
Examiner Name				
Attorney Docket Number	030229			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
2/	_	Garcion, E., et al., Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihyroxyvitamin D3 leads to early effects within central nervous system, Acta Neuropathol, 105:438-448, Jan. 2003.	
		Greenwood, J., et al., Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis, FASEB J. 17(8):905-7, published online March 5, 2003.	
		Mariani, S. M., Silencing Autoimmunity in Multiple Scierosis, Lupus, and Rheumatold Arthritis, Highlights From the 80 th Meeting of the American Association of Immunologists, May 8-10, 2003, Mediscape Molecular Medicine 5(1), 2003.	
		Wekerle, H., Tackling multiple sclerosis, Nature, 420:39-40, Nov. 7, 2002.	
		Youssef, S., et al., The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease, Nature, 420:78-84, Nov. 7, 2002.	
1	-	Zittermann, A., Review article, Vitamin D in preventive medicine: are we ignoring the evidence?, British Journal of Nutrition, 89:552-572, May 2003.	
		×	
· · · · · · · · · · · · · · · · · · ·		*	
	-	·	

	and the second second		
Examiner	Date	2/10/1	
Signature	Considered	3/16/07	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.